CQS Cayman’s Seres Therapeutics MCRB Stock Holding History

CQS Cayman’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,100	Closed	-$1.6M	–	120
2016 Q4	$1.6M	Hold	8,100	–	–	0.13%	86
2016 Q3	$1.99M	Hold	8,100	–	–	0.17%	81
2016 Q2	$4.71M	Buy	+8,100	New	+$4.75M	0.42%	58

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CQS Cayman's MCRB Position: Q1 2017 in Review

CQS Cayman sold out of Seres Therapeutics (MCRB) in Q1 2017, closing a stake of 8,100 shares — an estimated $1.6M sold.

CQS Cayman first reported a position in MCRB in Q2 2016 and held it in 3 quarters. The position peaked at $4.71M in Q2 2016. 79 funds tracked by Wall St. Rank hold MCRB as of Q1 2017.

CQS Cayman reported no remaining Seres Therapeutics position as of Q1 2017 after selling out during the quarter.
CQS Cayman sold 8,100 Seres Therapeutics shares in Q1 2017, an estimated $1.6M.
CQS Cayman first reported a position in Seres Therapeutics in Q2 2016 and held it in 3 quarters.
CQS Cayman's Seres Therapeutics position peaked at $4.71M in Q2 2016.
79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2017.

Based on CQS Cayman's 13F filing for Q1 2017, filed 15 May 2017.